Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners. As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i

i

Up-to-date Information

Up-to-Date Info: To find the latest CDC information on this topic go to: https://www.cdc.gov/coronavirus/2019-nCoV/index.html

Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States

Filetype[PDF-6.50 MB]


Select the Download button to view the document
This document is over 5mb in size and cannot be previewed
English

Details:

  • Corporate Authors:
  • Description:
    The Centers for Disease Control and Prevention (CDC) Interim Clinical Considerations provides additional information to healthcare professionals and public health officials on the use of COVID-19 vaccines. They are informed by the Advisory Committee on Immunization Practices (ACIP) and CDC’s recommendations, data submitted to the U.S. Food and Drug Administration (FDA) for Biologics License Application (BLA) or Emergency Use Authorization (EUA) of the vaccines, Emergency Use Instructions (EUI) for FDA-approved vaccines, other data sources, including the World Health Organization (WHO) emergency use listingpdf iconexternal icon (EUL) evaluation of COVID-19 vaccines and clinical trial results, general best practice guidelines for immunization, and expert opinion. These considerations apply only to the use of vaccine products currently approved or authorized in the United States. These considerations will be updated when additional information becomes available or if additional vaccine products are approved or authorized.
  • Content Notes:
    Purpose -- COVID-19 vaccines -- Groups recommended for vaccination -- Primary series -- Booster dose -- Guidance for COVID-19 vaccination for people who are moderately or severely immunocompromised -- Interchangeability of COVID-19 vaccine products -- Coadministration of COVID-19 vaccines with other vaccines -- COVID-19 vaccination and SARS-CoV-2 infection -- Vaccinating people with a known COVID-19 exposure or during COVID-19 outbreaks -- Considerations involving pregnancy, lactation, and fertility -- Vaccination of children and adolescents -- Patient counseling -- Considerations for mRNA COVID-19 vaccines: Pfizer-BioNTech and Moderna -- Considerations for Janssen COVID-19 Vaccine -- Contraindications and precautions -- Reporting of vaccine adverse events -- Laboratory testing -- Appendix A. Vaccine administration errors and deviations -- Appendix B. Guidance for People who are Moderately or Severely Immunocompromised and Vaccinated with Janssen COVID-19 Vaccine -- Appendix C: Triage of people with a history of allergies or allergic reactions -- Appendix D: Ingredients included in COVID-19 vaccines -- Appendix E. People who received COVID-19 vaccine outside the United States -- Appendix F. People who received COVID-19 vaccine as part of a clinical trial -- References -- Previous updates.
  • Subjects:
  • Document Type:
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

Supporting Files

More +

You May Also Like

Checkout today's featured content at stacks.cdc.gov